EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nuo Therapeutics's enterprise value is $34.72 Mil.
Nuo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.06 Mil. Therefore, Nuo Therapeutics's EV-to-EBITDA for today is -11.34.
The historical rank and industry rank for Nuo Therapeutics's EV-to-EBITDA or its related term are showing as below:
AURX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -73.01 Med: -3.74 Max: 0.17
Current: -11.34
During the past 13 years, the highest EV-to-EBITDA of Nuo Therapeutics was 0.17. The lowest was -73.01. And the median was -3.74.
AURX's EV-to-EBITDA is ranked worse than 100% of 462
companies
in the Biotechnology industry
Industry Median: 9.49
vs AURX: -11.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Nuo Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Nuo Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nuo Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Nuo Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuo Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nuo Therapeutics's EV-to-EBITDA falls into.
Nuo Therapeutics's current Enterprise Value is $34.72 Mil.
Nuo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuo Therapeutics (OTCPK:AURX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nuo Therapeutics's PE Ratio for today is calculated as:
Nuo Therapeutics's share price for today is $0.80.
Nuo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Nuo Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuo Therapeutics (Nuo Therapeutics) Business Description
Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AURX has been successfully added to your 